Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Casey Adams

Nurse Practitioner, Adult Health Gulfport, MS Nurse Practitioner

NPI 1437540184 CMS profile 10721361

1340 Broad Ave Ste 310, Gulfport, MS 39501

Open in the dashboard

General payments

$7,796

499 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Casey Adams of Gulfport, MS is reported in the CMS Open Payments database as having received $7,796 across 499 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,239 71
2024 General $1,698 106
2023 General $1,615 102
2022 General $1,837 119
2021 General $1,407 101

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Casey Adams
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Casey Adams were reported at $1,239. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Casey Adams Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,407 $138 $43–$438 $132
2022 $1,837 $165 $54–$494 $149
2023 $1,615 $178 $61–$549 $160
2024 $1,698 $186 $62–$575 $164
2025 $1,239 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $943 66 payments
  2. Lilly USA, LLC $916 54 payments
  3. GlaxoSmithKline, LLC. $783 70 payments
  4. Amgen Inc. $556 37 payments
  5. AstraZeneca Pharmaceuticals LP $484 24 payments
  6. AbbVie, Inc. $453 34 payments
  7. Novartis Pharmaceuticals Corporation $408 27 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $322 18 payments
  9. Sumitomo Pharma America, Inc. $320 19 payments
  10. Pfizer Inc. $319 18 payments
  11. Other $2,292 132 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,784 498 payments
  2. Education $12 1 payment
Products named General payments · program years 2021–2025
  1. Ozempic $709 48 payments
  2. MOUNJARO $649 32 payments
  3. TRELEGY ELLIPTA $558 50 payments
  4. GEMTESA $394 24 payments
  5. BREZTRI $327 14 payments
  6. Kerendia $322 18 payments
  7. AREXVY $273 23 payments
  8. RYBELSUS $272 21 payments
  9. UBRELVY $269 21 payments
  10. Otezla $267 19 payments
  11. Other $6,500 404 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 95 drugs

Part D claims

3,711

Median for Nurse Practitioner: 389

Drug cost

$455,631

Median for Nurse Practitioner: $21,885

Branded share of claims

21.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 78 $57,984
Ozempic Semaglutide Brand 47 $53,731
Trulicity Dulaglutide Brand 32 $41,455
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 47 $41,222
Jardiance Empagliflozin Brand 22 $32,713
Farxiga Dapagliflozin Propanediol Brand 25 $30,007
Gemtesa Vibegron Brand 53 $29,105
Eliquis Apixaban Brand 35 $24,490
Linzess Linaclotide Brand 22 $21,884
Mounjaro Tirzepatide Brand 19 $19,126

The 10 drugs with the highest cost, of 95 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$44,748

Medicare's payments for the services billed

Medicare patients

263

Average age 75

Services billed

1,077

182 women, 81 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Ischemic heart disease 32%
Diabetes 28%
COPD 23%
Osteoporosis 23%
Depression 22%
Chronic kidney disease 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 32 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $149
$149 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $125
$125 78 —
GEMTESA
  • Sumitomo Pharma America, Inc. $123
$123 53 —
MOUNJARO
  • Lilly USA, LLC $120
$120 19 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $97
$97 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 32 with Patron

Records

499 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record